[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,93,0,25,[9,50,83,114,175,196,233,263,296,329,356,389,420,448,506,554,581,606,631,654,681,706,734,758,785],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100599704","efficacy-of-gamma-auditory-stimulation-for-cognitive-decline-in-older-adults-study-1-100599704",false,"NCT07087951","Efficacy of Gamma Auditory Stimulation for Cognitive Decline in Older Adults (Study 1)","Development and Validation of an Innovative Gamma Auditory Stimulation System for Older Adults With Cognitive Decline: A Randomized, Double-blind, Placebo-controlled Study (Study 1)","Inclusion Criteria:\n\n1. Age over 60 years old.\n2. MMSE≤ 24\n3. CDR scores of 0.5 and 1\n4. Voluntary to sign the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Diagnosis of other psychiatric or neurological disorders\n2. Drug or alcohol addictions.\n3. Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.\n4. History of clinical stroke, major depressive disorder or dysthymic disorder according to the DSM-5.","ALL","60 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Animal studies have shown that 40 Hz auditory stimulation alone can improve spatial memory and reduce Aβ deposition. However, human studies using 40 Hz auditory stimulation alone remain limited. Therefore, this study will use a randomized, double-blind, placebo-controlled design to investigate the effects of 40 Hz auditory stimulation on cognitive function, EEG activity, sleep quality, and quality of life in older adults with mild cognitive impairment (MCI) or mild dementia.",[27,28,29],"EEG Brain Oscillations","Alzheimer's Disease (AD) and Related Disorders","Cognitive Dysfunction",[31,32,33,34,35,36],"endogenous gamma","EEG rhythms","resting-state EEG (rs-EEG)","Alzheimer's disease (AD)","Cognitive function","auditory stimulation","RECRUITING","2026-08-14",{"date":40,"type":41},"2026-08-17","ACTUAL",{"date":43,"type":41},"2025-11-14",{"date":45,"type":21},"2028-11-01",{"name":47,"class":48},"Chang Gung Memorial Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100440369","cognitive-impairment-in-colorectal-cancer-patients-receiving-cytotoxic-chemotherapy-100440369","NCT05014399","Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy","Chemo Brain","Inclusion Criteria:\n\n* Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.\n* A histologically-confirmed colorectal tumor\n* Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.\n* Patients must not have received cytotoxic chemotherapy previous to enrollment.\n\nExclusion Criteria:\n\n* Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n* Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys\n* Pregnant or breastfeeding\n* Any known brain metastases\n* Non-English speaking patients\n* Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.\n* Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.","18 Years",{"count":59,"type":21},60,"OBSERVATIONAL","The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.",[63,64,29,65,66,67,68,69],"Neoplasm, Colorectal","Cognitive Impairment","Cognitive Change","Chemo-brain","Chemo Fog","Chemotherapy Effect","Cognitive Decline",[71,72,73,74,64,55],"Palliative Care","Palliative Oncology","Supportive Care","Supportive Oncology","2026-08-13",{"date":38,"type":41},{"date":78,"type":41},"2021-09-20",{"date":80,"type":21},"2031-10",{"name":82,"class":48},"Joseph McCollom",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":49},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163","NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw",{"count":91,"type":21},30,[24],"The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[95,96,97,98,99,100,64,29],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog",[95,98,102,64,29,103,104,105],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","2026-08-12",{"date":38,"type":41},{"date":109,"type":41},"2026-06-23",{"date":111,"type":21},"2028-06",{"name":113,"class":48},"University of Alabama at Birmingham",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":121,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":155,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":49},"100454745","interventions-in-mathematics-and-cognitive-skills-100454745","NCT05201534","Interventions in Mathematics and Cognitive Skills","Interventions in Math Learning Disabilities: Cognitive and Neural Correlates","Inclusion Criteria:\n\n1. Elementary school aged children starting from first grade (6-12 years old)\n2. IQ: Participants with a Full Scale IQ \\> 70 on the Wechsler Abbreviated Scle of Intelligence (WASI-II).\n3. Identification of Mathematical Learning Disabilities: Scores below the 35th percentile percentile on symbolic number processing test in Numeracy Screener and two or more Wechsler Individual Achievement Test (WIAT-IV) math subtests\n4. Identification of typically developing children: Scores at or above the 35th percentile percentile on symbolic number processing test in Numeracy Screener and all WIAT-IV math subtests\n5. Normal or corrected-to-normal vision and no hearing impairments\n6. Inclusion in MRI scan session: Right-handed\n\nExclusion Criteria:\n\n1. History of neurological or psychiatric disorder (i.e., schizophrenia, psychosis, depression, or attention deficit hyperactivity disorder.)\n2. History of trauma involving head injury\n3. Consistent psychiatric medications\n4. Exclusion from MRI scan session: No major contraindication for magnetic resonance imaging (MRI) - braces, metal implants, pacemakers, vascular stents, metallic ear tubes, consistent exposure to metal, claustrophobia)",true,"6 Years","12 Years",{"count":125,"type":21},180,[24],"The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).",[129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,29,65,148,149,150,151,152,153,154],"Math Learning Disability","Child Development","Developmental Disability","Learning Disabilities","Learning Disabled","Learning Curve","Mathematics Disorder","Dyscalculia","Dyscalculia, Primary","Dyscalculia, Acquired","Specific Learning Disorder, With Impairment in Mathematics","Individuality","Behavior, Child","Behavior and Behavior Mechanisms","Behavior","Decision Making","Neuronal Plasticity","Cognition","Cognition Disorder","Cognitive Impairment, Mild","Cognitive Developmental Delay","Cognitive Orientation","Cognitive Delay, Mild","Cognitive Deficits, Mild","Cognitive Abnormality","Neuroscience",[156,157,158,159,160,161,162,163,164,165],"Numerical skills in children","Low math abilities","Mathematical Learning Disabilities","Mathematical Concepts","Mathematics","Transfer, Psychology","Generalization, Psychology","Early Intervention, Educational","Neural Pathways","Neural Networks, Computer","2026-08-07",{"date":168,"type":41},"2026-08-11",{"date":170,"type":41},"2023-05-05",{"date":172,"type":21},"2027-08-31",{"name":174,"class":48},"Stanford University",{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":49},"100513442","high-intensity-exercise-to-combat-vascular-and-cognitive-dysfunction-in-adults-with-hiv-100513442","NCT05965518","High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV","A Pilot Trial of High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Older Adults With HIV","Inclusion Criteria:\n\n* Age 50 years and older\n* Sedentary lifestyle, defined as \\\u003C 150 min\u002Fwk moderate physical activity as assessed by CHAMPS questionnaire\n* Neurocognitive Impairment (as assessed using the BRACE+\n* Prescribed HIV ART for ≥ 12 months, with no current use of older drugs with established mitochondrial toxicity\n* Able to speak, read, and write in English\n* Willingness to participate in all study procedures\n\nExclusion Criteria:\n\n* Diagnosis of mitochondrial disease\n* Active substance abuse or factors preventing compliance or safety\n* Uncontrolled hypertension, defined as resting BP \\> 150\u002F90 mmHG\n* Chronic kidney disease\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Acute myocardial infarction identified by medical history and ECG\n* Pulmonary disease requiring the use of supplemental oxygen\n* Poorly controlled diabetes\n* Neuropsychologically Intact\n* Orthopedic problems that limit ability to perform exercise\n* Simultaneous participation in another intervention trial","50 Years",{"count":59,"type":21},[24],"This is a single site, randomized exercise trial with individuals at least 50 years of age living with HIV who experience suboptimal cognition. The overall goals of this proposal are to determine whether 16 weeks of structured high-intensity interval training (HIIT) can overcome vascular and cognitive impairments (Aim 1) to a greater extent than continuous moderate exercise. Additionally, investigator will seek to identify barriers to engagement in exercise and the participants' perceptions of the study and exercise interventions (Aim 2). This study will enroll 60 participants in Birmingham, Alabama. Data collection will occur at each visit, with baseline data collected at the initial visit with a 3-month follow-up occurring following completion of the intervention.",[187,188,29],"HIV","Arterial Stiffness","2026-08-06",{"date":168,"type":41},{"date":192,"type":41},"2024-02-05",{"date":194,"type":21},"2028-12",{"name":113,"class":48},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":232},"100642012","phase-2-a-study-of-donanemab-ly3002813-in-participants-with-early-cognitive-decline-trailblazer-alz-7-100642012","NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)","A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology","Inclusion Criteria:\n\n* Have gradual and progressive cognitive decline for greater than or equal to ( ≥) 6 months.\n* Have least 1 core clinical feature of dementia with Lewy bodies (DLB).\n* Have a score ≥20 on Montreal Cognitive Assessment (MoCA).\n* Meet plasma P-tau217 criteria.\n* Have a cerebrospinal fluid (CSF) result consistent with the presence of brain amyloid pathology.\n* Have a CSF result consistent with the presence of alpha-synuclein pathology.\n* Have at least 1 reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant, and is familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n\nExclusion Criteria:\n\n* Have a disease or condition that could interfere with this study or is a current serious or unstable illness.\n* Have, or is suspected to have, a significant neurological disease (other than the studied condition) that affects the central nervous system and may affect the individual's cognition or ability to complete the study.\n* Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence and preventing the completion of the study.\n* Have clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions.\n* Have previously received amyloid-targeting therapy.\n* Active immunization against amyloid-beta.\n* Have a centrally read MRI that does not meet study entry criteria.\n* Have contraindication to MRI or PET scans.\n* Have any contraindication to lumbar puncture.","55 Years","85 Years",{"count":206,"type":21},350,[208],"PHASE2","The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.",[29,211,212,213],"Lewy Body Disease","Synucleinopathies","Amyloid",[215,216,217,218,219,220,221,222,29],"Mild Cognitive Impairment","Mild Dementia","Brain Diseases","Nervous System Diseases","Neurodegenerative Diseases","Neurocognitive Disorders","Cognition Disorders","Alzheimer Disease","2026-08-05",{"date":189,"type":41},{"date":226,"type":41},"2026-05-20",{"date":228,"type":21},"2028-08",{"name":230,"class":231},"Eli Lilly and Company","INDUSTRY",71,{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":49},"100650527","cognitive-effects-of-hesperidin-in-overweightobese-older-adults-100650527","NCT07750223","Cognitive Effects of Hesperidin in Overweight\u002FObese Older Adults","A Randomized Controlled Trial of Hesperidin for Improving Cognitive Function in Overweight and Obese Middle-Aged and Older Adults","Inclusion Criteria:\n\n* Age 55-75 years\n* BMI ≥ 24 kg\u002Fm² or waist circumference ≥ 90 cm (men) \u002F ≥ 85 cm (women)\n* Willing to participate and sign informed consent\n\nExclusion Criteria:\n\n* MMSE score \\\u003C 20\n* History of neurological diseases (Parkinson's, Alzheimer's, stroke, etc.)\n* Malignant tumors, severe liver\u002Fkidney\u002Fgastrointestinal diseases\n* Use of weight-loss drugs or antidepressants (except statins) within recent months\n* Strict vegetarians, binge eating disorder, heavy alcohol consumption\n* Participation in other intervention studies\n* Other conditions judged by investigators as unsuitable","75 Years",{"count":242,"type":21},105,[24],"A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults.\n\nA total of 105 participants, aged 55-75 years with a BMI ≥24 kg\u002Fm² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg\u002Fday), or high-dose hesperidin (600 mg\u002Fday).\n\nThe primary aim is to see if hesperidin supplementation enhances cognitive performance - specifically executive function, memory, and attention - and to explore any dose-response relationship.\n\nSecondary aims include examining changes in gut microbiota composition and related metabolites, as well as exploring potential mechanisms behind any observed effects.\n\nThe findings are expected to provide scientific evidence on whether hesperidin could serve as a nutritional strategy to support cognitive health in this population.",[29,246],"Overweight and Obesity",[248,249,250,251,252,253,254],"Hesperidin","Cognitive Function","Citrus Flavonoids","Gut Microbiota","Nutritional Intervention","Middle-aged and Elderly","Randomized Controlled Trial","2026-08-01",{"date":189,"type":41},{"date":258,"type":41},"2026-02-01",{"date":260,"type":21},"2027-03-30",{"name":262,"class":48},"Min Hou",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":271,"minAge":272,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100650035","cogot-telerehabilitation-for-adults-with-subjective-cognitive-complaints-100650035","NCT07743229","COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints","A Comprehensive Cognitive Assessment Protocol and Innovative Neurocognitive Telerehabilitation Pilot Program for Adults With Subjective Cognitive Complaints","CogSCC","Inclusion Criteria:\n\n* Endorsement of subjective cognitive complaints as indicated by a score ≥4 on the Healthy Brain 9 (HB9)\n* Community-dwelling adult aged 60 years or older, or adult aged 21 years or older with a diagnosis of Ehlers-Danlos Syndrome (EDS)\n* English as the primary language\n* Access to and ability to use a smartphone compatible with the NeuroUX platform\n* Access to a device capable of supporting a telerehabilitation visit, such as a phone, tablet, or laptop, and a reliable Wi-Fi or cellular internet connection\n* Able to participate in study assessment sessions as determined by the licensed, experienced telerehabilitation occupational therapist\n\nExclusion Criteria:\n\n* Diagnosis of dementia or mild cognitive impairment\n* Significant or unstable conditions or treatments for medical conditions that may impact cognition, such as traumatic brain injury or brain tumor\n* Inability to engage in study-related procedures as determined by the study team","MALE","21 Years",{"count":274,"type":21},16,[24],"This pilot study will evaluate a comprehensive cognitive assessment approach and personalized neurocognitive telerehabilitation intervention for adults with subjective cognitive complaints (SCC). The study includes older adults with SCC and adults with Ehlers-Danlos Syndrome (EDS) and SCC. Participants will complete pre- and post-treatment assessments and receive a 6-week COG+OT telerehabilitation intervention that combines cognitive rehabilitation and occupational therapy strategies to support everyday functional cognition.",[278,279,29],"Subjective Cognitive Complaints","Ehlers-Danlos Syndrome",[281,102,282,283,284,279],"Subjective cognitive complaints","Functional cognition","Occupational therapy","Cognitive rehabilitation","NOT_YET_RECRUITING","2026-07-29",{"date":288,"type":41},"2026-08-03",{"date":290,"type":21},"2026-09-01",{"date":292,"type":21},"2027-05-01",{"name":294,"class":48},"Medical University of South Carolina",2,{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":311,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100649134","protocolized-receptive-music-intervention-to-reduce-care-refusal-in-nursing-home-residents-with-major-neurocognitive-disorders-100649134","NCT07730957","Protocolized Receptive Music Intervention to Reduce Care Refusal in Nursing Home Residents With Major Neurocognitive Disorders","Impact of Protocolizing Receptive Music Intervention on Care Refusal During Hygiene Care in Nursing Home Residents With Major Neurocognitive Disorders","OPPOZIC'","RESIDENT ELIGIBILITY\n\nInclusion Criteria:\n\n* Living in a LNA Santé EHPAD (nursing home) as a permanent resident for at least 3 months\n* Diagnosed Alzheimer's disease or a related disorder, or confirmed cognitive decline shown by a Mini-Mental State Examination (MMSE - a short memory and thinking test) score of 24 or less within the past 12 months (including cases where the MMSE cannot be administered due to severe cognitive impairment)\n* Showing care refusal behavior, defined as an Agitation\u002FAggression item score on the NPI-ES scale (frequency × severity) greater than or equal to 4 at the time of inclusion\n* Resident and\u002For their legal representative or trusted person has given written consent to participate\n* Affiliated to a French social security scheme\n\nExclusion Criteria:\n\n* Uncompensated hearing loss with sensory isolation (unable to benefit from music therapy)\n* Documented end-of-life status in the medical record\n\nCAREGIVER ELIGIBILITY\n\nInclusion Criteria (Caregivers):\n\n* Adult (18 years of age or older)\n* Working in the care unit of an enrolled resident and performing hygiene\u002Fnursing care (bathing)\n* Able to read and write French\n* Affiliated to a French social security scheme\n* Has given written consent to participate\n\nExclusion Criteria (Caregivers):\n\n* Employment contract shorter than the resident's 3-month study follow-up period (i.e., unable to complete all 3 caregiver assessments)\n* Unable to provide informed consent to participate\n* Under legal protection as defined by Article 1121-8 of the French Public Health Code (under legal guardianship or deprived of liberty)\n* Not affiliated to a French social security scheme",{"count":59,"type":21},[24],"The goal of this randomized study is to find out whether using a structured, protocolized music program (MUSIC CARE©) during daily hygiene care can reduce care refusal in older adults with dementia (memory and thinking conditions) who live in nursing homes (EHPADs).\n\nWhat is \"care refusal\"? Care refusal (also called resistance to care) happens when a person with dementia refuses or becomes distressed during everyday care activities such as bathing, dressing, or taking medications. It is a very common situation in nursing homes that can be stressful for both residents and care staff.\n\nThe main questions this study aims to answer are:\n\n* Can a structured, daily music program reduce care refusal during bathing and hygiene care compared to current practice?\n* Does using music for 20 minutes during the care session work as well as - or differently from - using it both before and during care (40 minutes total)?\n* Does the music program also reduce distressing behavioral symptoms in residents?\n* Does it reduce the need for sedative or psychiatric medications?\n* Does it reduce professional burnout in caregivers who perform hygiene care?\n\nResearchers will compare three groups:\n\n* Group 1 (Control): Current practice - care staff may use MUSIC CARE© at their own discretion, as they already do\n* Group 2 (Music During Care): Structured use of MUSIC CARE© for 20 minutes during every hygiene care session, daily for 4 weeks\n* Group 3 (Music Before + During Care): Structured use of MUSIC CARE© for 20 minutes before and 20 minutes during every hygiene care session (40 minutes total), daily for 4 weeks\n\nNursing homes (not individual residents) are randomly assigned to a group.\n\nResidents and their caregivers will:\n\n* Have their level of care refusal recorded daily for 4 weeks\n* Have neuropsychiatric symptoms and medication use assessed at the start, Week 4, and Week 8\n* Caregivers will also complete a confidential and anonymous professional burnout questionnaire at 3 time points",[308,29,309,310],"Dementia","Psychomotor Agitation","Burnout, Professional",[308,312,313,314,315,316,317,318],"Music Therapy","Care Refusal","Receptive Music Intervention","Non-Pharmacological Intervention","Behavioral and Psychological Symptoms of Dementia","Nursing Home","Professional Burnout","2026-07-23",{"date":321,"type":41},"2026-07-28",{"date":323,"type":41},"2025-10-30",{"date":325,"type":21},"2027-06-30",{"name":327,"class":48},"LNA SANTE",12,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":337,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":49},"100648393","cognitive-dysfunction-and-delirium-after-tur-m-in-elderly-patients-100648393","NCT07719712","Cognitive Dysfunction and Delirium After TUR-M in Elderly Patients","Prediction of Postoperative Cognitive Dysfunction and Delirium: A Prospective Observational Study to Develop a Risk Score in Elderly Patients Undergoing Transurethral Resection","POCDTURMSTUD","Inclusion Criteria:\n\n* Age ≥65 years\n* Scheduled for transurethral resection procedure\n* ASA physical status I-III\n* Able to provide informed consent\n* Adequate cognitive function to complete preoperative assessment\n\nExclusion Criteria:\n\n* Pre-existing diagnosis of dementia or severe cognitive impairment (MoCA \\\u003C18)\n* Severe visual or hearing impairment preventing cognitive assessment\n* History of psychiatric disease requiring antipsychotic or sedative medication\n* Neurological disorders associated with increased delirium risk (e.g., Parkinson's disease, epilepsy)\n* Inability to complete study assessments","65 Years",{"count":339,"type":21},150,"Elderly patients undergoing transurethral resection are at increased risk of postoperative cognitive dysfunction (POCD) and delirium, which are associated with prolonged hospital stay, increased morbidity, and decreased quality of life. Identifying patients who are more likely to develop postoperative cognitive dysfunction or delirium remains a practical challenge in daily clinical practice. Better recognition of these patients may help tailor perioperative care and improve outcomes.\n\nThis prospective observational study aims to identify perioperative factors associated with POCD and delirium in elderly patients undergoing transurethral resection and to develop a clinically applicable risk prediction model. Cognitive function and delirium are assessed using the Montreal Cognitive Assessment (MoCA) and the Confusion Assessment Method (CAM).\n\nCognitive function and delirium will be evaluated using the Montreal Cognitive Assessment (MoCA) and the Confusion Assessment Method (CAM).\n\nThe results of this study may support clinicians in recognizing vulnerable patients earlier and may contribute to more individualized perioperative management.",[342,343,29],"Postoperative Delirium","Postoperative Cognitive Dysfunction",[343,345,346],"Delirium","Transurethral Resection","2026-07-20",{"date":349,"type":41},"2026-07-22",{"date":351,"type":41},"2026-04-05",{"date":353,"type":21},"2026-11-15",{"name":355,"class":48},"Muğla Sıtkı Koçman University",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":373,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100647436","transcranial-direct-current-stimulation-for-long-covid-brain-fog-and-fatigue-100647436","NCT07709234","Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue","The Impact of Transcranial Direct Current Stimulation on Quality of Life, Brain Fog, and Fatigue in Patients With Long COVID: Study Protocol of the NEUROSTIM-LC Study","NEUROSTIM-LC","Inclusion Criteria:\n\n* Adults aged between 18 and 70 years.\n* Diagnosis of long COVID according to World Health Organization criteria, defined as symptoms persisting for at least three months after acute SARS-CoV-2 infection and lasting for a minimum of two months without an alternative explanation.\n* Presence of persistent fatigue and\u002For cognitive impairment, commonly described as brain fog, attributed to long COVID and confirmed at screening.\n* Stable clinical condition allowing participation in the intervention and assessment procedures.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to transcranial direct current stimulation, including the presence of implanted electronic devices such as pacemakers or neurostimulators, intracranial metallic implants, or history of epilepsy or seizures.\n* History of neurological disorders that may affect cognitive function, including stroke, Parkinson's disease, or neurodegenerative disorders.\n* Pre-existing conditions associated with chronic fatigue or cognitive impairment prior to SARS-CoV-2 infection, such as fibromyalgia, chronic fatigue syndrome, or multiple sclerosis.\n* Severe psychiatric disorders, including psychosis or severe depression.\n* Substance abuse, including alcohol or drugs.\n* Current oncological treatment with chemotherapy or radiotherapy.\n* Pregnancy.\n* Any medical condition that, in the opinion of the investigators, may interfere with participation or with the interpretation of the results.","70 Years",{"count":366,"type":21},20,[24],"Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions involved in cognition, fatigue, and executive function.\n\nThe NEUROSTIM-LC study will evaluate the feasibility and potential effects of repeated tDCS sessions in adults with long COVID presenting fatigue and\u002For brain fog. Participants will receive 30 sessions of tDCS applied over the left dorsolateral prefrontal cortex. Assessments will be performed before and after the intervention to evaluate changes in quality of life, fatigue, cognitive function, brain metabolism, physical performance, autonomic function, sleep quality, psychological symptoms, respiratory function, and blood biomarkers.",[370,371,372,29],"Long COVID","Post-COVID Conditions","Fatigue",[374,375,102,370,98,376,377,378,379,380],"Transcranial direct current stimulation","tDCS","Quality of life","Cognitive impairment","Heart rate variability","PET-CT","Neuromodulation","2026-07-19",{"date":349,"type":41},{"date":384,"type":21},"2026-09-15",{"date":386,"type":21},"2028-03-01",{"name":388,"class":48},"University of Las Palmas de Gran Canaria",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":396,"minAge":203,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":49},"100609894","the-better-harder-faster-stronger-study-100609894","NCT07220512","The Better, Harder, Faster, Stronger Study","The BHFS Study (Better, Harder, Faster, Stronger): Does Neoadjuvant Chemotherapy Improve Fitness for Surgery?","Inclusion Criteria:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent.\n* Age \\> 55 years at the time of enrollment.\n* Newly diagnosed suspected ovarian\u002Fprimary peritoneal\u002Ffallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator.\n* Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter.\n* Ability to read, understand, and write the English language.\n* As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n* History of brain metastases.\n* History of poorly controlled psychiatric conditions, defined as hospitalization within the prior 3 months for psychiatric disorders, traumatic brain injury, cerebrovascular event, or dementia, per the enrolling investigator.\n* Use of anti-amyloid agents, cholinesterase inhibitors, or Memantine for Alzheimers\u002Fcognitive impairment, at the time of enrollment.\n* Vision impairment that would impede completion of study assessments, per enrolling investigator.","FEMALE",{"count":398,"type":21},35,"The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.",[401,402,403,29,404],"Frailty at Older Adults","Ovarian Cancer","Endometrial Cancer","Neoadjuvant Chemotherapy",[406,407,408,409,410],"Frailty","ovarian cancer","endometrial cancer","cognitive dysfunction","neoadjuvant chemotherapy","2026-07-14",{"date":413,"type":41},"2026-07-15",{"date":415,"type":41},"2025-07-28",{"date":417,"type":21},"2027-05",{"name":419,"class":48},"Wake Forest University Health Sciences",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":436,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100647582","neurocognitive-assessment-cnsl-and-lgg-100647582","NCT07710131","Neurocognitive Assessment CNSL and LGG","Neurocognitive Evaluation Using Digital Technology: A Pilot Study in Primary Central Nervous System Lymphoma and Low-grade Gliomas","Inclusion Criteria:\n\n* Histopathologically confirmed newly diagnosed primary CNS diffuse large B-cell lymphoma (DLBCL) OR\n* Histopathologically confirmed IDH-M low grade glioma diagnosis in the past 12 months who have not started tumor directed therapy (if applicable).\n* Age ≥ 18 years.\n* Ability to consent to study.\n\nExclusion Criteria:\n\n* Patients who have severe visual impairment that cannot be corrected with glasses to read regular sized print.\n* Patients who have known psychiatric or substance abuse disorders that would interfere with their cooperation in completing the requirements of the study.",{"count":428,"type":21},36,[24],"This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.",[432,433,29,434,435],"PCNSL","Brain Tumor","IDH Mutation","Low-grade Glioma",[437,438,439,29],"Primary Central Nervous System Lymphoma (PCNSL)","IDH-Mutant Low-Grade Glioma (LGG)","Brain Tumors","2026-07-13",{"date":442,"type":41},"2026-07-17",{"date":290,"type":21},{"date":445,"type":21},"2029-01-01",{"name":447,"class":48},"Dana-Farber Cancer Institute",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":121,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":474,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":49},"100643981","health-ahead-comparative-effectiveness-study-100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.",{"count":457,"type":21},1000000,[24],"The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[461,462,463,464,465,466,467,468,469,29,406,470,471,472,473],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Aging","Cardiovascular Diseases","Metabolic Syndrome","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[475,476,477,478,479,472,462,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Patient Engagement","Cardiopulmonary Exercise Testing","Body Composition","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Biological Age","Healthspan","Longevity","Life Expectancy","Chronic Disease","Cost-Effectiveness","Health Services Research","2026-06-20",{"date":499,"type":41},"2026-06-25",{"date":501,"type":21},"2026-06-09",{"date":503,"type":21},"2099-12-31",{"name":505,"class":231},"William Brandenburg, MD",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":121,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":515,"conditions":516,"keywords":526,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":49},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":457,"type":21},"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[467,517,518,493,468,519,29,469,406,520,521,308,470,471,522,523,524,472,525],"Mortality","All-cause Mortality","Neoplasms","Musculoskeletal Disease","Neurodegenerative Disease","Disability Physical","Environmental Exposure","Occupational Diseases","Social Determinants of Health",[527,528,529,530,531,532,533,534,535,536,537,538,539,472,540,541,483,484,481,491,542,543,544,545,546],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":548,"type":41},"2026-06-15",{"date":550,"type":41},"2026-04-25",{"date":503,"type":21},{"name":553,"class":231},"Longevity Metrics, Inc.",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":121,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":562,"conditions":563,"keywords":569,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":49},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":457,"type":21},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[467,564,565,517,469,468,29,566,519,406,470,567,522,568,308],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[492,483,484,481,570,540,542,491,493,571,572,573,541,574,537,543],"Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":576,"type":41},"2026-06-11",{"date":578,"type":41},"2025-02-09",{"date":503,"type":21},{"name":553,"class":231},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":121,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":49},"100555066","polyphenols-and-cognitive-decline-100555066","NCT06507254","Polyphenols and Cognitive Decline","MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE","Inclusion Criteria:\n\n* 50+ Years of age\n* Male or Female\n* At enhanced risk of Alzheimer's Disease (defined as family history of AD, 1st degree family member)\n* Habitually consume suboptimal diets such as typical Western Diet (i.e., high in animal products, refined carbohydrates and processed food)\n* Able to communicate well in English\n\nExclusion Criteria:\n\n* Vegan or Vegetarian\n* Presence of cognitive impairment at the time of recruitment into the study as measured by the Mini Mental Status Exam (MMSE, score 25-30) and Clinical Dementia Rating (CDR, score=0).\n* Pre-existing psychosis or psychiatric conditions\n* Currently receiving treatment for dementia\n* History of alcohol and\u002For substance abuse\u002Fdependence as determined by a positive endorsement on the MINI+\u002F If the MINI+ is positive for alcohol or drug dependence, or abuse, the participants will be excluded.\n* Heavy use of tobacco (greater than 1\u002F2 pack per day)\n* History of cerebrovascular events\n* Existing allergies to berry fruits\n* Use of oral\u002FIV antibiotics in the last 3 months. Use of probiotics in the last 1 month.\n* Recent Changes (last 3 months) in the use of psychoactive medications or other medications that interfere with the measured outcomes.\n* Frailty, malnutrition, or food allergy\u002Fintolerance requiring special diets.\n* Body weight at enrollment greater than 400lbs due to weight restrictions on the MRI table.\n* Women who are pregnant, lactating, or postpartum for less than 6months.\n* Women of childbearing age who are not practicing birth control or are planning to get pregnant during the study.\n\nUnable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign body, etc.)\n\n* Chronic Pain",{"count":590,"type":21},300,[24],"Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs.\n\nIn this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs.\n\nParticipants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.",[69,29],[595,596,597,598],"Polyphenols","Mediterranean Diet","Gut Microbiome","Alzheimers Disease",{"date":576,"type":41},{"date":601,"type":41},"2025-01-09",{"date":603,"type":21},"2029-12-31",{"name":605,"class":48},"University of California, Los Angeles",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":49},"100643034","vortioxetine-for-cognitive-function-in-alk-positive-nsclc-treated-with-lorlatinib-100643034","NCT07633626","Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib","Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of ALK\u002FROS1-positive non-small cell lung cancer (NSCLC), stage IIIB\u002FIV.\n* Currently receiving lorlatinib as part of the standard therapeutic regimen.\n* Documented neurocognitive adverse events (NAEs) attributable to lorlatinib.\n* Age \\>= 18 years.\n* ECOG performance status 0-2.\n* Ability to understand and sign informed consent.\n* Expected survival \\>= 6 months.\n* Planned initiation of vortioxetine as part of standard care.\n* Ability to complete neuropsychological tests and questionnaires in Spanish.\n\nExclusion Criteria:\n\n* Prior diagnosis of major cognitive impairment unrelated to cancer treatment.\n* Current use of another antidepressant that cannot be discontinued.\n* Uncontrolled major psychiatric disorder.\n* History of uncontrolled epilepsy or recent seizures.\n* Severe hepatic or renal impairment.\n* Known hypersensitivity to vortioxetine.\n* Participation in another clinical trial within the past 30 days.\n* Inability to provide informed consent.\n* Life expectancy \\\u003C 3 months.\n* Contraindications to vortioxetine (e.g., concomitant MAOI use).\n* Prior vortioxetine use.\n* Severe psychiatric disorders or significant cognitive impairment unrelated to lorlatinib.",{"count":614,"type":21},24,"This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements.\n\nLorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but it causes neuropsychological adverse events (NAEs) in approximately 42% of patients, including cognitive impairment, mood changes, and speech disturbances. Vortioxetine has demonstrated cognitive improvement in depressed patients and in preclinical models of androgen deprivation therapy-induced cognitive impairment.\n\nTwenty-four adult patients with ALK\u002FROS1-positive NSCLC receiving lorlatinib as standard care and prescribed vortioxetine (10-20 mg\u002Fday) for NAE management will be enrolled. Comprehensive neuropsychological assessments and quality-of-life questionnaires will be conducted at baseline, week 6, week 12, and month 6 to document changes in cognitive function, depressive symptoms, and quality of life.",[617,618,619,620,29,621],"Advanced ALK\u002FROS1-positive NSCLC","Carcinoma, Non-Small-Cell Lung (NSCLC)","Lung Adenocarcinoma","ALK-positive Non-small Cell Lung Cancer (NSCLC)","Depression","2026-06-04",{"date":624,"type":41},"2026-06-08",{"date":626,"type":41},"2026-03-10",{"date":628,"type":21},"2027-11-10",{"name":630,"class":48},"Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":17,"minAge":337,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":22,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":295},"100503106","up-2-study-cognitively-engaging-walking-exercise-and-neuromodulation-to-enhance-brain-function-in-older-adults-100503106","NCT05830942","Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults","Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults","Inclusion Criteria:\n\n* Age 65+\n* Objective executive function decline, based on standardized cognitive assessments.\n* Subjective cognitive decline, based on the question: \"During the past 12 months, have you experienced confusion or memory loss that is happening more often or getting worse?\"\n* Ability to walking independently for 6 minutes (use of cane permitted)\n\nExclusion Criteria:\n\n* Major cognitive disorder that interferes with independence\n* Percentile score less than 10th percentile on standardized cognitive assessments\n* Medications that are thought to influence tDCS neuroplasticity.\n* Contraindications to tDCS or MRI.",{"count":639,"type":21},120,[24],"Declines in cognitive function and walking function are highly intertwined in older adults. A therapeutic approach that combines complex (cognitively engaging) aerobic walking exercise with non-invasive electrical brain stimulation may be effective at restoring lost function. This study tests whether electrical stimulation of prefrontal brain regions is more beneficial than sham stimulation.",[29,643,644],"Mobility Limitation","Frail Elderly","2026-06-02",{"date":647,"type":41},"2026-06-03",{"date":649,"type":41},"2024-04-15",{"date":651,"type":21},"2027-04-30",{"name":653,"class":48},"University of Florida",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":662,"targetDuration":4,"studyType":22,"phases":664,"briefSummary":665,"conditions":666,"keywords":669,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":49},"100633442","brain-stimulation-and-cognitive-training-for-mci-100633442","NCT07526740","Brain Stimulation and Cognitive Training for MCI","Combining Brain Stimulation With Computerized Cognitive Training for MCI","RISE pilot","Inclusion Criteria:\n\n1. Age 60-85 (inclusive).\n2. English as a first\u002Fprimary language.\n3. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.\n4. Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.\n5. Meets the following requirements for current and prior medications and treatments:\n\n   1. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n   2. Anti-amyloid monoclonal antibody therapy for AD\u002FMCI:\n\n      * Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.\n      * Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.\n   3. Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.\n6. Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).\n\nExclusion Criteria:\n\n1. Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.\n2. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).\n3. Daily\u002Fweekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.\n4. History of significant or unstable condition\u002Fs or treatments for these condition\u002Fs that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).\n5. Plan to initiate treatment for AD\u002FMCI with monoclonal antibody therapy during study participation.\n6. For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.\n7. Current use of any implanted brain stimulation device.\n8. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n9. MRI contraindications (e.g., ferromagnetic implants, claustrophobia).\n10. Unable or unwilling to engage in BrainHQ activities.\n11. TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.",{"count":663,"type":21},50,[24],"This is a randomized clinical trial of a treatment that combines non-invasive brain stimulation with computerized cognitive training (CCT) for people with mild cognitive impairment (MCI). The form of brain stimulation used in this study is accelerated intermittent theta burst stimulation (iTBS). All participants receive the same amount of iTBS and are randomly assigned to engage in one of two types of CCT. The goals of the study are to see if this combined treatment is feasible and acceptable to people with MCI and whether combined iTBS and CCT improves memory, thinking skills, mood, and daily function.",[667,668,220,29,221],"Mild Cognitive Impairment (MCI)","Mild Neurocognitive Disorder",[467,670,671,215,672,673],"Alzheimers","Memory Loss","Transcranial Magnetic Stimulation","cognitive training",{"date":675,"type":41},"2026-05-22",{"date":677,"type":41},"2026-03-16",{"date":679,"type":21},"2030-05-31",{"name":294,"class":48},{"id":682,"slug":683,"hasResults":12,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":12,"sex":17,"minAge":337,"maxAge":4,"enrollmentInfo":689,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":691,"conditions":692,"keywords":693,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":699,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":295},"100460246","mobility-disorders-assessment-in-patients-with-mild-cognitive-disorders-100460246","NCT05273125","MOBility Disorders Assessment in Patients With Mild COGnitive Disorders","Multimodal and Longitudinal Assessment of MOBility Disorders in Patients With Mild COGnitive Disorders","COG-MOB","Inclusion Criteria:\n\n* Patient being diagnosed with MCI, according to the 2011 criteria\n* Able to walk 4 meters with or without technical assistance\n* Comprehension of French language allowing the realization of the neuropsychological assessment\n\nExclusion Criteria:\n\n* Severe visual or hearing impairment that does not allow the assessment\n* Severe pathology that makes follow-up impossible\n* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security insurance, refusal to sign consent form\n* Under legal protection (guardianship, curatorship, safeguard of justice)",{"count":690,"type":21},417,"Mild cognitive impairment (MCI) is defined by lower performance in one or more cognitive domains with preservation of independence in functional abilities. Sixteen percent of community-dwelling older people (over 65 years) live with MCI. They are both cognitively and physically vulnerable. From a cognitive perspective, they are susceptible to converting to the dementia stage at an annual rate of 10%. From a physical perspective, the proportion of slow gait or neurological gait abnormalities can reach 46% in the population with MCI. Falls in turn increase the risk of accelerated cognitive decline and the risk of institutionalization. In the absence of a curative treatment for dementia, it is essential to have an effective and personalized prevention strategy by identifying the predictive factors for falls in this at-risk population with MCI.\n\nThe research goals of this project are 1) to identify specific predictors for falls in clinic attendees with MCI in preparation for a definitive, fully powered study across France, and 2) to demonstrate the feasibility of a pragmatic fall risk assessment in MCs, whatever its setting and location.\n\nWe aim to prospectively follow-up people diagnosed with MCI and aged above 65 years old in four MCs in France (three in the North (one community-based MC), and one in the Centre) for one year.",[29],[694,695,696,697,698],"Mild Cognitive Impairement","Falls","Predictive factors","Elderly","Gait disorders assessment.",{"date":675,"type":41},{"date":701,"type":41},"2022-09-09",{"date":703,"type":21},"2026-09",{"name":705,"class":48},"University Hospital, Lille",{"id":707,"slug":708,"hasResults":12,"nctId":709,"briefTitle":710,"officialTitle":711,"acronym":4,"eligibilityCriteria":712,"healthyVolunteers":121,"sex":17,"minAge":713,"maxAge":714,"enrollmentInfo":715,"targetDuration":4,"studyType":22,"phases":717,"briefSummary":718,"conditions":719,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":727,"lastUpdatePostDateStruct":728,"startDateStruct":729,"completionDateStruct":731,"leadSponsor":732,"locationsCount":49},"100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","16 Years","80 Years",{"count":716,"type":21},134,[24],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[720,721,722,723,724,29,725,726],"Psychotic Disorders","Cannabis Use Disorder","Cannabis Dependence","Cannabis Use","Schizophrenia; Psychosis","Memory Impairment","Neuroimaging","2026-05-19",{"date":675,"type":41},{"date":730,"type":41},"2022-04-21",{"date":417,"type":21},{"name":733,"class":48},"Douglas Mental Health University Institute",{"id":735,"slug":736,"hasResults":12,"nctId":737,"briefTitle":738,"officialTitle":739,"acronym":4,"eligibilityCriteria":740,"healthyVolunteers":12,"sex":17,"minAge":713,"maxAge":4,"enrollmentInfo":741,"targetDuration":4,"studyType":22,"phases":742,"briefSummary":743,"conditions":744,"keywords":747,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":751,"lastUpdatePostDateStruct":752,"startDateStruct":753,"completionDateStruct":755,"leadSponsor":756,"locationsCount":49},"100637794","fareon-open-label-device-clinical-trial-100637794","NCT07600320","Fareon Open Label Device Clinical Trial","Microtesla Magnetic Therapy (MMT) Treatment of Cognitive Impairment: Open Label Pilot Study","IncInclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Any sex\u002Fgender\n* 16 years of age or older\n* English Speaking\n* Experiencing symptoms of at least self-reported mild cognitive impairment associated with a confirmed diagnosis of a condition such as Long COVID, Traumatic Brain Injury, other Acquired Brain Injuries, and other neurodegenerative diagnoses including but not limited to Alzheimer's disease\n* Individuals of childbearing age agreeing to use a highly effective form of birth control for the duration of their participation\n* Willing and able to sign informed consent or have a parent or LAR able to sign informed consent form\n* Willing and able to attend all study visits virtually or in person\n\nExclusion Criteria:\n\nIndividual who meets any of the following criteria will be excluded from participation in this study:\n\n* Enrollment in another interventional clinical trial in the last 90 days or during the study period\n* Change in anti-depressant or other psychoactive medication or dose in the last 90 days\n* Cranially implanted devices or metal\n* Pacemaker\n* History of seizure disorder\n* Pregnant or plan to become pregnant during the study as indicated by proof of a positive pregnancy test\n* Inability to achieve appropriate positioning of the study device on the head\n* Any medical, psychiatric, or neurological condition, or concurrent treatment, that in the opinion of the Principal Investigator would interfere with study participation, interpretation of results, or pose additional risk to the participant.",{"count":91,"type":21},[24],"The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME\u002FCFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.",[29,745,746],"Acquired Brain Injury","Traumatic Brain Injury",[370,748,749,750],"Myalgic encephalomyelitis\u002FChronic fatigue syndrome","Neurodegenerative","Alzheimer's disease","2026-05-14",{"date":226,"type":41},{"date":754,"type":21},"2026-05-01",{"date":651,"type":21},{"name":757,"class":48},"Icahn School of Medicine at Mount Sinai",{"id":759,"slug":760,"hasResults":12,"nctId":761,"briefTitle":762,"officialTitle":762,"acronym":763,"eligibilityCriteria":764,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":765,"targetDuration":4,"studyType":22,"phases":766,"briefSummary":768,"conditions":769,"keywords":773,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":777,"lastUpdatePostDateStruct":778,"startDateStruct":779,"completionDateStruct":781,"leadSponsor":783,"locationsCount":4},"100485768","phase-1-minocycline-in-neurocognitive-outcomes---sickle-cell-disease-100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":91,"type":21},[767],"PHASE1","Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[770,64,69,65,29,771,772],"Sickle Cell Disease","Cognitive Deficit","Neuroinflammatory Response",[774,775,409,776],"sickle cell disease","benign hematology","neuroinflammation","2026-05-11",{"date":751,"type":41},{"date":780,"type":21},"2026-12-01",{"date":782,"type":21},"2028-06-15",{"name":784,"class":48},"University of Cincinnati",{"id":786,"slug":787,"hasResults":12,"nctId":788,"briefTitle":789,"officialTitle":790,"acronym":4,"eligibilityCriteria":791,"healthyVolunteers":121,"sex":17,"minAge":792,"maxAge":203,"enrollmentInfo":793,"targetDuration":4,"studyType":22,"phases":795,"briefSummary":796,"conditions":797,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":799,"lastUpdatePostDateStruct":800,"startDateStruct":802,"completionDateStruct":804,"leadSponsor":806,"locationsCount":49},"100558115","bwell-d-pilot-randomized-controlled-trial-100558115","NCT06546917","bWell-D Pilot Randomized Controlled Trial","The bWell Cognitive Care Platform: A Pilot Feasibility Study in Patients With Depression","Inclusion Criteria:\n\n* 19-55 years old\n* Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD as assessed by a standardized psychiatric interview (SCID-5-RV) conducted by a trained clinician.\n* Patients will be euthymic or mildly depressed (defined by a Montgomery-Asberg Depression Rating Scale \\[MADRS\\] score \\\u003C 19)\n* Patients will report subjective cognitive deficits at baseline, as indicated by a total Perceived Deficits Questionnaire - Depression 20 \\[PDQ-D-20\\] score \\> 20 at study enrollment.\n* If using antidepressants, participants will be on stable antidepressant therapy for at least 4 weeks prior to randomization. All concomitant doctor-prescribed medications must be at a stable dose for 4 weeks prior to the randomization visit.\n* If undergoing psychotherapy, participants will be on stable adjunct psychotherapy for at least 8 weeks prior to randomization\n* If comorbid diagnosis of attention deficit hyperactivity disorder (ADHD), patients must be on stable dose of stimulants for at least 4 weeks prior to randomization.\n* Participants will be able to follow written and verbal instructions in English\n\nExclusion Criteria:\n\n* Moderate - severely depressed patients will be excluded at this point due to acceptability concerns (e.g. potential for cybersickness)\n* Presence of significant neurological disorders, head trauma, or other unstable medical conditions. These conditions may adversely impact cognitive functioning and influence study results.\n* Presence of other psychiatric disorder (e.g. anxiety, psychotic disorder) that may be considered primary.\n* Meeting DSM-5 criteria for alcohol or other substance use disorder within three months prior to the randomization visit.\\*\n* Use of benzodiazepine medications more than three times per week and\u002For within 24 hours of baseline or close out visit\n* Use of cannabis or alcohol within 24 hours, or tobacco within 30 minutes of baseline or close out visit\n* Suicidal ideation or self harm\n* Completion of previous cognitive remediation\n\nAdditionally, patients will be excluded from the study if they meet any of the following criteria due to contraindications with MRI scanning:\n\n* Retained wires from an electronic implant that has been removed (i.e. pacemaker wires not attached to a pacemaker)\n* Cardiac pacemaker or defibrillator\n* Metal in eye or orbit\n* Ferromagnetic aneurysm clip\n* Pregnancy\n* Makeup tattoos that are not designed to fade over time\n* Stainless steel intrauterine device (IUD)\n\nDepending on the individual situation, they MAY NOT be able to participate if they have\u002Fhad any of the following:\n\n* Artificial Heart Valve\n* Ear or eye implant\n* Brain aneurysm clip\n* Implanted electronic device (i.e. drug infusion pump, electrical stimulator)\n* Coil, catheter, or filter in any blood vessel\n* Orthopedic hardware (artificial joint, plate, screw, rod)\n* Shrapnel, bullets, or other metal fragments\n* Surgery, medical procedure or tattoos (including tattooed eyeliner) in the last six weeks\n* Other metallic prostheses\n\nIf the participant has any of the above, or any safety issues arise during MRI screening process, the individual case will be reviewed by UBC Hospital MR Technologist and\u002For Radiologist and a case-by-case decision will be made regarding participation.\n\nAdditionally, for the healthy participant recruitment, the eligibility criteria is as follows:\n\nInclusion Criteria for healthy controls:\n\n\\- 19-55 years old\n\nExclusion criteria for healthy controls:\n\n* History of any psychiatric disorder, as assessed by a standardized psychiatric diagnostic interview\n* Presence of significant neurological disorder, head trauma, or other unstable medical conditions which may adversely impact cognitive functioning\n* Presence of any physical mobility issues that limit arm or neck movement","19 Years",{"count":794,"type":21},40,[24],"The goal of this clinical trial is to determine the acceptability, feasibility, and validity of the bWell Cognitive Care Platform for Depression (bWell-D), a novel Virtual Reality (VR) cognitive assessment and remediation tool, in depressed populations. The main questions are:\n\n* Do patients with Major Depressive Disorder (MDD) find the bWell-D cognitive assessment battery and protocol feasible, tolerable, and acceptable?\n* Do patients with Major Depressive Disorder (MDD) find the 8 week bWell-D remediation protocol feasible, tolerable, and acceptable?\n\nFollowing initial cognitive assessment, researchers will assess feasibility outcomes in the bWell remediation arm to a VR scenes experience arm to learn more about the feasibility of bWell for cognitive assessment and remediation.\n\nPatients will:\n\n* Complete an initial bWell cognitive assessment session\n* Randomized to either receive bWell cognitive remediation or a VR scenes experience twice a week for eight weeks\n* Complete cognitive\u002Ffunctional\u002Fclinical assessments and EEG at baseline, midpoint and endpoint of the remediation protocol, as well as two MRI scans and measures of tolerability, engagement, and enjoyment",[798,29],"Depressive Disorder, Major","2026-04-22",{"date":801,"type":41},"2026-04-28",{"date":803,"type":41},"2025-01-01",{"date":805,"type":21},"2026-08",{"name":807,"class":48},"University of British Columbia"]